FOLR1 FDA (ELAHERE) for Ovarian Carcinoma

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is an FDA-approved qualitative immunohistochemical assay using a mouse monoclonal anti-FOLR1 antibody intended for use in the assessment of Folate Receptor alpha (FRα) protein in formalin-fixed, paraffin-embedded (FFPE) ovarian cancer tissue on a VENTANA BenchMark ULTRA instrument. FOLR1 is indicated as an aid in identifying patients with ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer), whose tumors have FRα expression in ≥75% tumor cells staining at 2+/3+ intensity, who are eligible for treatment with ELAHERE (mirvetuximab soravtansine-gynx). This test is available through the ImmunoGen sponsored FOLR1 testing program initiative called FR-ASSIST. A separate test request form is required. Please visit the FOLR1 Ovarian Cancer Testing Program page for more information and to download the Test Request Form.